SCHEMBL4508316

SCHEMBL4508316

N#CCOc1cccc(Cl)c1CC1CCN(C2CCCCC2)C1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.49
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35
PDE4D Q08499 1/20 0.35
PDE7A Q13946 1/20 0.35
PDE1C Q14123 1/20 0.35
PDE3A Q14432 1/20 0.35
LMNA P02545 2/20 0.35
C5AR1 P21730 1/20 0.34
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
POLB P06746 1/20 0.32
ROCK2 O75116 1/20 0.31
GRM5 P41594 1/20 0.31
TSHR P16473 1/20 0.31
CNR1 P21554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513738 0.86 HSD11B1 (0.52) HSD11B1LMNAALDH1A1GAAKMT2A
SCHEMBL4516365 0.84 HSD11B1 (0.54) HSD11B1LMNAALDH1A1GAAMEN1
SCHEMBL5541309 0.84 HSD11B1 (0.49) HSD11B1LMNAALDH1A1GAAMEN1
SCHEMBL3553955 0.83 HSD11B1 (0.64) HSD11B1LMNAALDH1A1MEN1KMT2A
SCHEMBL4516967 0.83 HSD11B1 (0.56) HSD11B1LMNAC5AR1ALDH1A1GAA
SCHEMBL4523062 0.83 HSD11B1 (0.48) HSD11B1LMNAALDH1A1GAAMEN1
SCHEMBL4516411 0.82 HSD11B1 (0.47) HSD11B1LMNA
SCHEMBL2990265 0.79 HSD11B1 (0.59) HSD11B1LMNAALDH1A1GAAMEN1
SCHEMBL2988726 0.79 HSD11B1 (0.59) HSD11B1LMNAALDH1A1GAAMEN1
SCHEMBL2988725 0.79 HSD11B1 (0.59) HSD11B1LMNAALDH1A1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885PDE1A 1703/4885PDE1B 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.